Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
Roos S. G. Sablerolles, Wim J. R. Rietdijk, Abraham Goorhuis, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 10, pp. 951-963
Open Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients
Corine H. GeurtsvanKessel, Daryl Geers, Katharina S. Schmitz, et al.
Science Immunology (2022) Vol. 7, Iss. 69
Open Access | Times Cited: 404
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 178
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Wei-Yu Chi, Yen-Der Li, Hsin‐Che Huang, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 166
T Cell Responses to SARS-CoV-2
Alessandro Sette, John Sidney, Shane Crotty
Annual Review of Immunology (2023) Vol. 41, Iss. 1, pp. 343-373
Closed Access | Times Cited: 114
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
Karin Hardt, An Vandebosch, Jerald Sadoff, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 12, pp. 1703-1715
Open Access | Times Cited: 63
The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines
Bruna Aparecida Souza Machado, Katharine Valéria Saraiva Hodel, Larissa Moraes dos Santos Fonseca, et al.
Vaccines (2022) Vol. 10, Iss. 4, pp. 591-591
Open Access | Times Cited: 62
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
Leanne P. M. van Leeuwen, Corine H. GeurtsvanKessel, Pauline M. Ellerbroek, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 149, Iss. 6, pp. 1949-1957
Open Access | Times Cited: 60
Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects
Zhan Zhang, Qi Shen, Haocai Chang
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 55
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study
Kathryn S. Hensley, Marlou J. Jongkees, Daryl Geers, et al.
PLoS Medicine (2022) Vol. 19, Iss. 10, pp. e1003979-e1003979
Open Access | Times Cited: 39
Challenges in the Vaccination of the Elderly and Strategies for Improvement
Gatot Soegiarto, Dewajani Purnomosari
Pathophysiology (2023) Vol. 30, Iss. 2, pp. 155-173
Open Access | Times Cited: 30
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial
Ngoc H. Tan, Daryl Geers, Roos S. G. Sablerolles, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 8, pp. 901-913
Open Access | Times Cited: 27
The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic
Linda Petrone, Alessandro Sette, Rory D. de Vries, et al.
Pathogens (2023) Vol. 12, Iss. 7, pp. 862-862
Open Access | Times Cited: 25
Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK
Jia Wei, Philippa C. Matthews, Nicole Stoesser, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 23
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters
Luca M. Zaeck, Ngoc H. Tan, Wim J. R. Rietdijk, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
Jie Deng, Yirui Ma, Qiao Liu, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 17, pp. 10752-10752
Open Access | Times Cited: 35
Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial
Pengfei Jin, Xiling Guo, Wei Chen, et al.
PLoS Medicine (2022) Vol. 19, Iss. 5, pp. e1003953-e1003953
Open Access | Times Cited: 34
Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis
Zejun Li, Shouhuan Liu, Fengming Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 29
Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines
Astrid Korning Hvidt, Eva Anna Marianne Baerends, Ole S. Søgaard, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 28
Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study
Winsley Rose, Reshma Raju, Sudhir Babji, et al.
The Lancet Regional Health - Southeast Asia (2023) Vol. 12, pp. 100141-100141
Open Access | Times Cited: 20
Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly
Isabella A. T. M. Ferreira, Colin Y. C. Lee, William S. Foster, et al.
Cell Reports (2023) Vol. 42, Iss. 8, pp. 112991-112991
Open Access | Times Cited: 16
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis
Alberto San Francisco Ramos, Carolina Liu-Sanchez, Tatiana Bovill Rose, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 266-282
Open Access | Times Cited: 6
COVID-19 vaccines: A comprehensive review of safety and efficacy
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Elsevier eBooks (2025), pp. 685-777
Closed Access
Autoimmune Skin Disease Exacerbations Following COVID-19 Vaccination
Grant Sprow, Mohsen Afarideh, Joshua Dan, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 22
Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study
Adrian M. Shields, Sian Faustini, Harriet J. Hill, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 22
Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape
Rituparna Das, Randall N. Hyer, Paul R. Burton, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top